Gene therapy halts progression of cerebral adrenoleukodystrophy in clinical trial – Science Daily
Science Daily |
Gene therapy halts progression of cerebral adrenoleukodystrophy in clinical trial
Science Daily In a recent clinical trial, a gene therapy to treat cerebral adrenoleukodystrophy (CALD) — a neurodegenerative disease that typically claims young boys’ lives within 10 years of diagnosis — effectively stabilized the disease’s progression in 88 … Bluebird’s gene therapy halts progression of ‘devastating’ disease cALDFierceBiotech NEJM Publishes Interim Data from Study of Gene Therapy in LorenzoRare Disease Report |
|
Synthego And Thermo Fisher To Manufacture, Distribute Synthetic Guide RNA Products For CRISPR
Bio-IT World “Thermo Fisher Scientific prides itself in having a reputation of providing top-quality, reliable products and services to the scientific community,” Helge Bastian, Vice President and General Manager of Synthetic Biology for Thermo Fisher Scientific … |
FierceBiotech |
Bluebird’s gene therapy halts progression of ‘devastating’ disease …
FierceBiotech A single dose of Bluebird Bio’s gene therapy for cerebral adrenoleukodystrophy (cALD) stabilized the disease in 15 of 17 patients over more than two years of … Gene therapy halts progression of cerebral adrenoleukodystrophy in …Science Daily NEJM Publishes Interim Data from Study of Gene Therapy in LorenzoRare Disease Report bluebird bio (BLUE): Interim Results Preview A Significant Catalyst …StreetInsider.com |
WRAL Tech Wire |
Heat Bio’s Pelican subsidiary strikes deal with Selexis to advance cancer immunotherapy
WRAL Tech Wire Durham, N.C. — Pelican Therapeutics, a subsidiary of Durham-based Heat Biologics Inc., has entered a service agreement with Geneva-based Selexis SA to advance development of Pelican’s cancer-fighting therapy candidates. Pelican intends to leverage … |
Crowdfund Insider |
Desktop Genetics Now Live on SyndicateRoom: Utilizing AI in Customizing CRISPR Libraries
Crowdfund Insider Desktop Genetics Ltd (DTG), a software company revolutionising the way biologists use CRISPR genome editing technology, and online investment platform SyndicateRoom have just opened a £1.5 million investment round. DTG plans to use the funds to … |